Table 4.
CHIKV vaccine candidates in clinical development.
| Vaccine strategy | Candidate name | Sponsor | Non-clinical development | Phase 1 | Phase 2 | References |
|---|---|---|---|---|---|---|
| Whole inactivated | – | USAMRIID and WRAIR | Immunogenicity and efficacy in mice and NHP | Completed | (164) | |
| BBV87 | Bharat Biotech International | Immunogenicity and efficacy in mice | CTRI/2017/02/007755 | (165) | ||
| Live attenuated | TSI-GSD-218 (181/clone 25) | Unites States Army Medical Research Institute of Infectious Diseases | Immunogenicity and efficacy in mice and NHP | Completed | (166–168) | |
| VLA1553 | Valneva Austria GmbH | Immunogenicity and efficacy in mice and NHP | NCT03382964 | (169–171) | ||
| Viral vectored | MV-CHIK | Themis Bioscience GmBH | Immunogenicity and efficacy in NHP | EudraCT-2013-001084-23 |
NCT02861586 NCT03101111 NCT03028441 NCT03635086 NCT03807843 |
(109, 172–174) |
| ChAdOx1 Chik | Jenner Institute, University of Oxford | Immunogenicity and efficacy in mice | NCT03590392 | (175, 176) | ||
| Virus like particles | VRC-CHKVLP059-00-VP | NIAID | Immunogenicity and efficacy in mice and NHP |
NCT01489358 NCT03028441 |
NCT02562482 | (108, 177, 178) |
| PXVX0317 (former name: VRC-CHKVLP059-00-VP) | Emergent BioSolutions | NCT03483961 | ||||
| mRNA | VAL-181388 | Moderna Therapeutics | Immunogenicity and efficacy in mice; immunogenicity in NHP | NCT03325075 |